Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells
Adoptive cancer immunotherapy using chimeric antigen receptor (CAR) engineered T-cells holds great promise, although several obstacles hinder the efficient generation of cell products under good manufacturing practice (GMP). Patients are often immune compromised, rendering it challenging to produce...
Main Authors: | May C. I. van Schalkwyk, Sjoukje J. C. van der Stegen, Leticia Bosshard-Carter, Helen Graves, Sophie Papa, Ana C. Parente-Pereira, Farzin Farzaneh, Christopher D. Fisher, Andrew Hope, Antonella Adami, John Maher |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/7/1797 |
Similar Items
-
Chimeric Antigen Receptor beyond CAR-T Cells
by: Vicky Mengfei Qin, et al.
Published: (2021-01-01) -
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
by: Mohamed-Reda Benmebarek, et al.
Published: (2019-03-01) -
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
by: Thivyan Thayaparan, et al.
Published: (2017-12-01) -
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant
by: Li Q, et al.
Published: (2020-11-01) -
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
by: Dongfang Liu, et al.
Published: (2020-08-01)